Debts
€1.0m 75% of the balance sheet
Financial debts 20%Suppliers 59%Taxes and wages 12%Other 9%
Of this, €1.0m falls due within a year.
CONSORTIUM PHARMACEUTIQUE DE BELGIQUE
Lifetime
19 annual accounts with figures on one time axis, 20 filings since 2006peak €423,747 (2019)
€381,555▲ 4.9%
lowest -€29,319 (2017)
€70,413▲ 1.8%
peak €340,056 (2025)
€340,056▲ 26.1%
€1.0m▲ 13.9%
peak 7.4 FTE (2019)
2.4 FTEunchanged
Board3 names since 2021
3 directorsCaroline DECARPENTRIE and 2 others
Owners
Documentsfilings and deeds
16-07-202677 days late
2025financial year
3 directors reappointed 15-01Equity from €269,643 to €340,056Cash from €159,857 to €265,028
Key points
from the 2025 annual accountsChecked score
85
Excellent
Financially stronger than 53% of micro companies in retail trade (NACE 47)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,275 companies (NACE 47, micro).
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.3%
01-2025: 0.3%● unchanged vs 12-2024
02-2025: 0.3%● unchanged vs 01-2025
03-2025: 0.3%● unchanged vs 02-2025
04-2025: 0.5%▲ +0.2 percentage points vs 03-2025
05-2025: 0.9%▲ +0.4 percentage points vs 04-2025
06-2025: 0.2%▼ -0.7 percentage points vs 05-2025
07-2025: 0.2%● unchanged vs 06-2025
08-2025: 0.2%● unchanged vs 07-2025lowest value
09-2025: 0.2%● unchanged vs 08-2025lowest value
10-2025: 0.2%● unchanged vs 09-2025lowest value
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.4%▲ +0.2 percentage points vs 03-2026
05-2026: 0.7%▲ +0.3 percentage points vs 04-2026
06-2026: 0.8%▲ +0.1 percentage points vs 05-2026
07-2026: 1.2%▲ +0.4 percentage points vs 06-2026highest value
08-2026: 0.3%▼ -0.9 percentage points vs 07-2026
09-2026: 0.3%● unchanged vs 08-2026
10-2026: 0.3%● unchanged vs 09-2026
11-2026: 0.3%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Last filed accounts filed 77 days late; 1 of the last 3 accounts late
Sector: Retail trade (NACE 47)
lowers risk
Founded in 2005
Size: 2.4 FTE, total assets €1.4m
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 41% of them on solvency, 32% on liquidity, 62% on profitability and 77% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 30-09-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 3,818 companies had the same profile as CONSORTIUM PHARMACEUTIQUE DE BELGIQUE has now. Each dot stands for 10 companies, two years later.
95.1%
were still trading
3.7%
stopped another way
1.0%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of CONSORTIUM PHARMACEUTIQUE DE BELGIQUE itself: 0.3% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,818 companies, not a prediction for CONSORTIUM PHARMACEUTIQUE DE BELGIQUE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €25,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.04 (0.94 in 2024), below the usual 1.5. Short-term debt is 74.1% and cash 19.6% of total assets. 74.9% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 77 days late
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 16-07-2026, 77 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
77 days late
2024
6 days late
2023
8 days late
2022
3 days late
2021
12 days late
2020
1 day early
2019
on the day
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 15 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-09-2026 is due by 30-04-2027. Nothing is late today. The company usually files around 9 May (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-09-2026 year end09-11-2026 today30-04-2027 deadline
Board and ownership
- BEL MANAGEMENT 45%score 92equity €540,156 (2025) · 30-06-2025 annual accounts of BEL MANAGEMENT
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0874822610
3 directors reappointed
Caroline DECARPENTRIE, Marie DECARPENTRIE and Charles RANSART · “1. l'exploitation d'officines pharmaceutiques dans le respect des règles édictées par l'Ordre des…” (deed in French) · General meeting of 27-12-2024 · Gazette deed
New establishment in Uccle
COPHARBEL HOMBORCH, Homborch 71
New establishment in Uccle
Engelandstraat 366
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| CONSORTIUM PHARMACEUTIQUE DE BELGIQUE Uccle | €1.4m | €381,555 | 25.1% | 2.4 |
| ORTHO SINA Jette | €1.4m | €279,184 | 70.7% | 1.8 |
| PROMEDIONICS Berchem-Sainte-Agathe | €1.4m | €556,877 | 28.8% | 2.7 |
| MEDLINE Tongeren-Borgloon | €1.0m | €404,816 | 63.8% | 2.6 |
| ALEXANDER ORTHOPEDIE Destelbergen | €1.6m | €479,000 | 35.3% | 1.8 |
| APOTHEEK DE PRETER A. Sint-Niklaas | €1.3m | €284,368 | 24.0% | 1.9 |
| MEDICAL PRECISION Destelbergen | €1.8m | €486,409 | 40.2% | 3.4 |
These companies have the same main activity as CONSORTIUM PHARMACEUTIQUE DE BELGIQUE: retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses (NACE 47741). They are comparable in size and age: total assets between €1m and €1.8m, founded between 2001 and 2010.
Official details
Source: KBO- Status
- Active since 01-07-2005Normal situation
- Activity
- Retail sale of medical and orthopaedic goods, excluding prescription glasses and lensesNACE 47741and 1 other
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 30-09-2024
- Establishment units
- 2.158.169.5297912 Frasnes-lez-Anvaing, since 11-07-2005
- 2.213.994.5141180 Uccle, since 01-10-2012and 1 other
- Financial year end
- 30 September
- Peppol
- Reachable since 19-02-2026
Annual accounts to 30-09-2025
- ≈ €1.4mestimated
- €1.4m▲ 16.8%
- Employeeson 30-09-2025
- 3=
- Filing
- Filed on 16-07-2026
Insights on CONSORTIUM PHARMACEUTIQUE DE BELGIQUE
CONSORTIUM PHARMACEUTIQUE DE BELGIQUE has existed since 2005. The gross margin grew from €107,218 in 2007 to €381,555 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about CONSORTIUM PHARMACEUTIQUE DE BELGIQUE
- What is the company number of CONSORTIUM PHARMACEUTIQUE DE BELGIQUE?
- The company number of CONSORTIUM PHARMACEUTIQUE DE BELGIQUE is 0874.822.610. The VAT number is the same number with BE in front: BE 0874.822.610.
- Where is CONSORTIUM PHARMACEUTIQUE DE BELGIQUE based?
- The registered office is at Neerstallesteenweg 485, 1180 Uccle.Company details
- What does CONSORTIUM PHARMACEUTIQUE DE BELGIQUE do?
- According to the KBO register, the main activity is retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses (NACE 47741).
- What is the legal form of CONSORTIUM PHARMACEUTIQUE DE BELGIQUE?
- CONSORTIUM PHARMACEUTIQUE DE BELGIQUE is a public limited company (NV).
- When was CONSORTIUM PHARMACEUTIQUE DE BELGIQUE founded?
- CONSORTIUM PHARMACEUTIQUE DE BELGIQUE was founded on 01-07-2005.
- Is CONSORTIUM PHARMACEUTIQUE DE BELGIQUE still active?
- Yes, CONSORTIUM PHARMACEUTIQUE DE BELGIQUE is an active enterprise in the KBO register.
- How many employees does CONSORTIUM PHARMACEUTIQUE DE BELGIQUE have?
- CONSORTIUM PHARMACEUTIQUE DE BELGIQUE had an average of 2.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does CONSORTIUM PHARMACEUTIQUE DE BELGIQUE fall under?
- In its 30-09-2024 annual accounts, CONSORTIUM PHARMACEUTIQUE DE BELGIQUE states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of CONSORTIUM PHARMACEUTIQUE DE BELGIQUE?
- The turnover in financial year 2025 is ≈ €1.4m. This figure is estimated from the gross margin of €381,555 and 47 comparable companies (NACE 477). It probably lies between €1.0m and €2.1m. In financial year 2024 turnover was €0.
- Is CONSORTIUM PHARMACEUTIQUE DE BELGIQUE profitable?
- In financial year 2025, CONSORTIUM PHARMACEUTIQUE DE BELGIQUE made a profit of €70,413.
- Where can I find the annual accounts of CONSORTIUM PHARMACEUTIQUE DE BELGIQUE?
- CONSORTIUM PHARMACEUTIQUE DE BELGIQUE filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CONSORTIUM PHARMACEUTIQUE DE BELGIQUE due?
- CONSORTIUM PHARMACEUTIQUE DE BELGIQUE must file the annual accounts for financial year 2026 by 30-04-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.